STAT Plus: Soleno Therapeutics responds to short seller’s Prader-Willi drug safety claims
Adam’s Biotech Scorecard
Adam’s Biotech Scorecard is a subscriber-only newsletter offering unfiltered analysis from Adam Feuerstein, a veteran reporter with decades of experience covering the intersection of Wall Street and biotechnology. It’s delivered on Thursday mornings, and STAT+ subscribers can sign up here.
Latest
STAT Plus: FDA ‘uncertainty’ forces Krystal Biotech to shutter cancer drug trial
STAT Plus: Alnylam could be the next mega-cap biotech
STAT Plus: Are we sure Vinay Prasad’s ouster is positive for biotech?
STAT Plus: Why Sarepta may not survive its current gene therapy crisis
STAT Plus: Eyes on Soleno’s Prader-Willi drug launch
STAT Plus: The year is half over. Here’s where the biotech industry stands
STAT Plus: Here’s how Insmed grows to be the next $100 billion biotech
All Coverage
